Tryptamine Therapeutics (AU:TYP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tryptamine Therapeutics Limited has announced the appointment of Hamish George as the new Chief Financial Officer, bringing his decade-long expertise in finance and commercial experience to the clinical-stage biotech company. George’s previous roles include Director at Bio101 Financial Advisory and CFO for multiple organizations, poised to aid the company’s development of novel psilocybin-based therapies. The company expressed gratitude to former CFO Jim O’Neill for his contributions and smooth transition of responsibilities to George.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.